(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Guaranteeing Quality Medical care with Federal medical care Benefit Plans. - 2Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- 3Which Diet Prompts the Incomparable Wellbeing Results?
- 4How comfort foods trigger pleasure in our brains
- 5Vote in favor of your #1 Sort of Convenience for a Family
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- European Travel Objections for 2024
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- Desired Travel Objections Worldwide: Where to Go Straightaway
- 6 Asian Urban communities to Visit
- Instructions to Augment the Presentation of Your Kona SUV
- The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Figure out How to Stay away from Normal Handshaking Missteps
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
